risks and costs. Pharmaceuticals do not lose their capacity for harm after moving from behind the pharmacist’s counter to in front of it; misuse of OTC drugs remains a major cause of emergency department visits, hospitalization, and death. Closer attention should be paid to how such drugs are promoted to consumers.

Jeremy A. Greene, MD, PhD
Niteesh K. Choudhry, MD, PhD
Aaron S. Kesselheim, MD, JD, MPH
Troyen A. Brennan, MD
William Shrank, MD, MPP

Author Affiliations: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, Massachusetts (Drs Greene, Choudhry, Kesselheim, and Shrank); and CVS Caremark (Dr Brennan). Dr Greene is now with Johns Hopkins University.

Author Contributions: Dr Greene had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Greene, Choudhry, Kesselheim, Shrank.

Acquisition of data: Greene, Brennan, Shrank.

Analysis and interpretation of data: Greene, Shrank.

Drafting of the manuscript: Greene.

Critical revision of the manuscript for important intellectual content: Greene, Choudhry, Kesselheim, Brennan, Shrank.

Obtained funding: Shrank.

Administrative, technical, or material support: Brennan, Shrank.

Study supervision: Greene, Shrank.

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Greene reported receiving research grants from CVS Caremark, and royalties from Johns Hopkins University Faculty Fellowship in Entrepreneurship Research from the Kauffman Foundation, a career development award from the Agency for Healthcare Research and Quality, a Robert Wood Johnson Foundation Investigator Award in Health Policy Research, and serving as an expert witness on behalf of a class of individual claimants against AstraZeneca alleging improper promotion of esomeprazole (Nexium). Ms Donohue reported receiving research grants from CVS Caremark, Aetna, the National Association of Chain Drug Stores, Teva Pharmaceuticals Inc, and Lilly. Dr Brennan reported receiving compensation from the Virginia M. Sharfstein Foundation, filing a lawsuit against AstraZeneca, and receiving stock in CVS Caremark.

Funding/Support: This work was supported by a research grant from CVS Caremark.

Role of the Sponsor: Dr Brennan participated in the project but CVS Caremark placed no restrictions on and had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

Additional Contributions: Mary Kenneally, BA, Elaine Klubuk, BA, Benjamin Smith, BA, and Kellie Swanton, BA, participated in the coding of the advertisements and Jessica Myers, PhD, conducted all statistical analyses. All of the individuals are associated with the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, Massachusetts, and did not receive compensation for their work.


